Royce & Associates LP Innoviva, Inc. Transaction History

Royce & Associates LP

$9.35 Billion
Q3 2025

A detailed history of Royce & Associates LP transactions in Innoviva, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 505,906 shares of INVA stock, worth $11.3 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

505,906

Previous 68,252 641.23%

Holding current value

$11.3 Million

Previous $1.37 Million 573.38%

% of portfolio

0.1%

Previous 0.01%

34 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 12, 2025	BUY	$18.17 - $20.92 $7.95 Million - $9.16 Million	437,654 Added 641.23%	505,906 $9.23 Million
Q2 2025 Aug 11, 2025	SELL	$17.1 - $21.8 $32,011 - $40,809	-1,872 Reduced 2.67%	68,252 $1.37 Million
Q1 2025 May 06, 2025	BUY	$17.21 - $18.98 $180,687 - $199,271	10,499 Added 17.61%	70,124 $1.27 Million
Q4 2024 Feb 10, 2025	BUY	$17.35 - $20.32 $29,789 - $34,889	1,717 Added 2.97%	59,625 $1.03 Million
Q3 2024 Nov 06, 2024	BUY	$16.33 - $20.04 $219,050 - $268,816	13,414 Added 30.15%	57,908 $1.12 Million

Q2 2024 Aug 13, 2024	SELL	$14.4 - $16.4 $354,412 - $403,636	-24,612 Reduced 35.61%	44,494 $729,000
Q1 2024 May 13, 2024	SELL	$14.56 - $16.78 $219,433 - $252,891	-15,071 Reduced 17.9%	69,106 $1.05 Million
Q4 2023 Feb 12, 2024	SELL	$12.32 - $16.27 $398,835 - $526,708	-32,373 Reduced 27.78%	84,177 $1.35 Million
Q3 2023 Nov 09, 2023	SELL	$12.37 - $13.89 $22,439 - $25,196	-1,814 Reduced 1.53%	116,550 $1.51 Million
Q2 2023 Aug 07, 2023	BUY	$11.39 - $13.72 $10,752 - $12,951	944 Added 0.8%	118,364 $1.51 Million
Q1 2023 May 04, 2023	BUY	$10.73 - $13.6 $193,719 - $245,534	18,054 Added 18.17%	117,420 $1.32 Million
Q4 2022 May 23, 2023	SELL	$11.8 - $13.78 $213,037 - $248,784	-18,054 Reduced 15.38%	99,366 $1.32 Million
Q4 2022 Feb 13, 2023	BUY	$11.8 - $13.78 $214,229 - $250,175	18,155 Added 22.36%	99,366 $1.32 Million
Q3 2022 Nov 03, 2022	BUY	$11.61 - $15.22 $33,831 - $44,351	2,914 Added 3.72%	81,211 $943,000
Q2 2022 Aug 04, 2022	SELL	$14.32 - $19.88 $31,389 - $43,576	-2,192 Reduced 2.72%	78,297 $1.16 Million
Q1 2022 May 05, 2022	SELL	$15.39 - $20.25 $161,164 - $212,058	-10,472 Reduced 11.51%	80,489 $1.56 Million
Q4 2021 Feb 07, 2022	BUY	$15.91 - $18.72 $73,186 - $86,112	4,600 Added 5.33%	90,961 $1.57 Million
Q3 2021 Nov 10, 2021	BUY	$13.06 - $17.24 $14,117 - $18,636	1,081 Added 1.27%	86,361 $1.44 Million
Q2 2021 Aug 06, 2021	BUY	$11.45 - $13.96 $32,483 - $39,604	2,837 Added 3.44%	85,280 $1.14 Million
Q1 2021 May 10, 2021	BUY	$11.06 - $12.87 $41,231 - $47,979	3,728 Added 4.74%	82,443 $985,000
Q4 2020 Feb 08, 2021	BUY	$9.33 - $12.48 $19,509 - $26,095	2,091 Added 2.73%	78,715 $975,000
Q3 2020 Nov 12, 2020	BUY	$10.33 - $14.49 $7,602 - $10,664	736 Added 0.97%	76,624 $801,000
Q2 2020 Aug 07, 2020	BUY	$11.49 - $15.26 $2,366 - $3,143	206 Added 0.27%	75,888 $1.06 Million
Q1 2020 May 12, 2020	SELL	$8.11 - $15.23 $2,165 - $4,066	-267 Reduced 0.35%	75,682 $890,000
Q4 2019 Feb 06, 2020	BUY	$10.28 - $14.38 $154,857 - $216,620	15,064 Added 24.74%	75,949 $1.08 Million
Q3 2019 Nov 13, 2019	BUY	$10.05 - $14.55 $263,239 - $381,108	26,193 Added 75.5%	60,885 $642,000
Q2 2019 Aug 12, 2019	BUY	$13.1 - $14.95 $195,766 - $223,412	14,944 Added 75.67%	34,692 $505,000
Q1 2019 May 09, 2019	BUY	$13.69 - $20.06 $252,566 - $370,086	18,449 Added 1420.25%	19,748 $277,000
Q4 2018 Feb 11, 2019	SELL	$13.96 - $18.26 $8,585 - $11,229	-615 Reduced 32.13%	1,299 $23,000
Q3 2018 Nov 13, 2018	BUY	$13.63 - $15.7 $9,799 - $11,288	719 Added 60.17%	1,914 $29,000
Q2 2018 Aug 09, 2018	BUY	$13.44 - $17.59 $7,015 - $9,181	522 Added 77.56%	1,195 $16,000
Q1 2018 May 14, 2018	SELL	$13.8 - $16.99 $2,401 - $2,956	-174 Reduced 20.54%	673 $11,000
Q4 2017 Feb 09, 2018	BUY	$11.73 - $14.75 $1,067 - $1,342	91 Added 12.04%	847 $12,000
Q3 2017 Nov 13, 2017	BUY	$12.06 - $14.12 $9,117 - $10,674	756	756 $11,000

Others Institutions Holding INVA

# of Institutions

281

Shares Held

82.7M

Call Options Held

13.2K

Put Options Held

156K

View Full List

About Innoviva, Inc.

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.55B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

More about INVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.

Account

Royce & Associates LP Innoviva, Inc. Transaction History